2. Signaling Pathways
  3. Neuronal Signaling
    Protein Tyrosine Kinase/RTK
  4. Trk Receptor

Trk Receptor

Tropomyosin related kinase receptor

Trk Receptor

Related Products

PDF 0.95 MB

Trk receptors are a family of three receptor tyrosine kinases (TrkA, TrkB, and TrkC), each of which can be activated by one or more of four neurotrophins-nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), and neurotrophins 3 and 4 (NT3 and NT4).

TrkA, TrkB, and TrkC are transmembrane proteins that comprise the TRK receptor family. These receptor tyrosine kinases are expressed in human neuronal tissue, and play an essential role in both the physiology of development and function of the nervous system through activation by neurotrophins (NTs). The latter are specific ligands known as NGF for TrkA, BDGF, and NT-4/5 for TrkB and NT3 for TrkC, respectively.

The binding of the ligand to the receptor triggers the oligomerisation of the receptors and phosphorylation of specific tyrosine residues in the intracytoplasmic kinase domain. This event results into the activation of signal transduction pathways leading to proliferation, differentiation and survival in normal and neoplastic neuronal cells.

Trk Receptor Isoform Specific Products:

Trk Receptor Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-143557
    Trk-IN-7
    		Inhibitor
    Trk-IN-7 (compound I-6) is a potent TRK inhibitor with IC50s of ranging from 0.25-10 nM for TRKA, TRKB and TRKC, respectively. Trk-IN-7 shows inhibition against EML4-ALK (IC50<15 nM) ALK G1202R, ALK C1156Y, ALK R1275Q, ALK F1174L, ALK L1197M, and ALK G1269A (IC50=5-50 nM).
    Trk-IN-7
  • HY-145105
    Inonophenol C
    Inonophenol C is a neurotrophic and protective agent against neurodegenerative disorders.
    Inonophenol C
  • HY-146115
    TRK-IN-19
    		Inhibitor
    TRK-IN-19 (Compound I-10 ) is a potent inhibitor of TRK (TRKA IC50 = 1.1 nM, TRKAG595R IC50 = 5.3 nM). TRK-IN-19 has the potential for the research of cancer diseases.
    TRK-IN-19
  • HY-144732
    TRK/ALK-IN-1
    		Inhibitor
    TRK/ALK-IN-1 (compound 21) is a potent and dual inhibitor of TRK and ALK. TRK/ALK-IN-1 in the enzymatic assays is in good accordance with anti-proliferative activity with IC50 values of 2.2, 9.3 and 38 nM towards TRKA, ALKWT and ALKL1196M, respectively. TRK/ALK-IN-1 has the potential for the research of cancer diseases.
    TRK/ALK-IN-1
  • HY-174161
    Type II TRK inhibitor 3
    		Inhibitor
    Type II TRK inhibitor 3 (Compound 18d) is a Type II TRK inhibitor with IC50 values of 0.82, 1.82, and 0.12 nM for TRKAWT/G595R/G667C, respectively. Type II TRK inhibitor 3 exhibits antitumor activity.
    Type II TRK inhibitor 3
  • HY-163004
    Type II TRK inhibitor 2
    		Inhibitor
    Type II TRK inhibitor 2 (compound 40l) is a selective type II TRK inhibitor with plasma stability and moderate hepatic microsomal stability. Type II TRK inhibitor 2 significantly inhibits Km-12, Ba/F3-TRKAG595R and Ba/F3-TRKAG667C cell proliferation (IC50: 4.1 nM, 41.5 nM, 1.4 nM). Type II TRK inhibitor 2 can be used to study NTRK fusion cancers.
    Type II TRK inhibitor 2
  • HY-P991322
    Anti-NGF/bNGF Antibody (AS2886401-00)
    		Inhibitor
    Anti-NGF/bNGF Antibody (AS2886401-00) is a human monoclonal antibody (mAb) targeting NGF/bNGF. Anti-NGF/bNGF Antibody (AS2886401-00) inhibits cytosolic Ca2+ influx. Anti-NGF/bNGF Antibody (AS2886401-00) produces a long-lasting analgesic effect on pain during exercise in a rat model of OA. Anti-NGF/bNGF Antibody (AS2886401-00) can be used in Osteoarthritis research.
    Anti-NGF/bNGF Antibody (AS2886401-00)
  • HY-146521
    TRK-IN-15
    		Inhibitor
    TRK-IN-15 is a potent inhibitor of TRK. Protein kinases play a critical role in the control of cell growth and differentiation and are responsible for the control of a wide variety of cellular signal transduction processes. TRK-IN-15 has the potential for the research of TRK-related diseases (extracted from patent WO2012034091A1, compound X-55).
    TRK-IN-15
  • HY-B0168BS
    Levomilnacipran-d5 hydrochloride
    		Activator
    Levomilnacipran-d5 ((1S,2R)-Milnacipran-d5) hydrochloride is deuterium labeled Levomilnacipran hydrochloride (HY-B0168B). Levomilnacipran ((1S,2R)-Milnacipran) hydrochloride is the enantiomer of Milnacipran (HY-B0168) and a strong substrate of P-gp that can cross the blood-brain barrier. Levomilnacipran hydrochloride is a serotonin and norepinephrine reuptake inhibitor, with IC50 values of 10.5 nM and 19.0 nM, and Ki values of 92.2 nM and 1.2 nM for human norepinephrine transporter (NET) and serotonin transporter (SERT), respectively. Levomilnacipran hydrochloride has antidepressant and anxiolytic activities. Levomilnacipran hydrochloride can be used for the research of depression.
    Levomilnacipran-d<sub>5</sub> hydrochloride
  • HY-143561
    Trk-IN-8
    		Inhibitor
    Trk-IN-8 is a potent TRK inhibitor with IC50s of 0.42, 0.89 and 1.5 nM for TRKAa, TRKA(G595R) and TRKC(G623R), respectively (WO2021115401A1, compound 3).
    Trk-IN-8
  • HY-N15532
    Phenylmethyl 6-O-α-L-arabinofuranosyl-β-D-glucopyranoside
    		Modulator
    Phenylmethyl 6-O-α-L-arabinofuranosyl-β-D-glucopyranoside (Compound 12) is a nerve growth factor (NGF) secretion promoter, which is found in plants of the genus Piper. Phenylmethyl 6-O-α-L-arabinofuranosyl-β-D-glucopyranoside is promising for research of neurodegenerative diseases (such as Parkinson's disease and Alzheimer's disease) and diabetic polyneuropathy.
    Phenylmethyl 6-O-α-L-arabinofuranosyl-β-D-glucopyranoside
  • HY-150561
    Trk-IN-20
    		Inhibitor
    Trk-IN-20 is a kind of 3-vinylindazole derivatives. Trk-IN-20 suppresses Trk kinases functions by phosphorylation inhibition of TrkA/B/C with IC50 values of 1.6 nM, 2.9 nM and 2.0 nM, respectively.
    Trk-IN-20
  • HY-149965
    TRK-IN-23
    		Inhibitor
    TRK-IN-23 (compound 24b) is a potent and orally active TRK inhibitor with IC50 values of 0.5 nM, 9 nM, 14 nM, 4.4 nM, and 4.8 nM against TRKA, TRKC, TRKAG595R, TRKAF589L, and TRKAG667C, respectively. TRK-IN-23 indues apoptosis of Ba/F3-TRKAG595Rand Ba/F3-TRKAG667C cells.
    TRK-IN-23
  • HY-P991413
    ZEB85
    		Activator
    ZEB85 is a human monoclonal antibody (mAb) targeting TrkB. ZEB85 activates TrkB and its downstream signaling cascades and increases neuronal activity. ZEB85 prevents β-amyloid toxicity in cultured hippocampal neurons. ZEB85 can be used in Alzheimer's disease (AD) research.
    ZEB85
  • HY-146522
    TRK-IN-16
    		Inhibitor
    TRK-IN-16 is a potent inhibitor of TRK. Protein kinases play a critical role in the control of cell growth and differentiation and are responsible for the control of a wide variety of cellular signal transduction processes. TRK-IN-16 has the potential for the research of TRK-related diseases (extracted from patent WO2012034091A1, compound X-21).
    TRK-IN-16
  • HY-160166
    TRK-IN-26
    		Inhibitor
    TRK-IN-26 (compound 12) is a TRK inhibitor with potential for cancer research.
    TRK-IN-26
  • HY-161775
    RET/TRKA-IN-1
    		Inhibitor
    RET/TRKA-IN-1 (Compound 13) is a dual inhibitor for RET (IC50=0.375 µM) and TRKA. RET/TRKA-IN-1 inhibits cell viability of LC-2 and KM12, with GI50 of 0.72 and 0.25 μM. RET/TRKA-IN-1 arrests the cell cycle at G1 phase.
    RET/TRKA-IN-1
  • HY-112436A
    (3S,4R)-PF-6683324
    		Inhibitor
    (3S,4R)-PF-6683324 is a tropomyosin-related kinase (Trk) inhibitor extracted from patent WO2015092610A1 example 9. (3S,4R)-PF-6683324 has the potential for the research of pain and cancer.
    (3S,4R)-PF-6683324
  • HY-146755
    TIY-7
    		Inhibitor
    TIY-7 is a selective and orally active tropomyosin receptor kinase (TRK) inhibitor. TIY-7 shows enzyme inhibitory activity with IC50s of 2.9, 1.1, 0.7, 0.8, 0.8, 0.2 nM for TRKA, TRKAG595R, TRKAG667C, TRKAF589L, TRKCG623R, TRKCG696A, respectively. TIY-7 shows anti-tumor potency in mouse xenograft model.
    TIY-7
  • HY-146519
    TRK-IN-14
    		Inhibitor
    TRK-IN-14 is a potent inhibitor of TRK. Protein kinases play a critical role in the control of cell growth and differentiation and are responsible for the control of a wide variety of cellular signal transduction processes. TRK-IN-14 has the potential for the research of TRK-related diseases (extracted from patent WO2012034091A1, compound X-47).
    TRK-IN-14
Cat. No. Product Name / Synonyms Application Reactivity
Trk Receptor Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.